As filed with the Securities and Exchange Commission on March 11, 2024
Registration No. 333-276408
Registration No. 333-270883
Registration No. 333-266747
Registration No. 333-263453
Registration No. 333-254098
Registration No. 333-237173
Registration No. 333-229592
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE AMENDMENT TO
Form S-8 Registration No. 333-276408
Form S-8 Registration No. 333-270883
Form S-8 Registration No. 333-266747
Form S-8 Registration No. 333-263453
Form S-8 Registration No. 333-254098
Form S-8 Registration No. 333-237173
Form S-8 Registration No. 333-229592
UNDER
THE
SECURITIES ACT OF 1933
HARPOON THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware |
|
47-3458693 |
(State or Other Jurisdiction of
Incorporation or Organization) |
|
(I.R.S. Employer
Identification No.) |
611 Gateway Boulevard
South San Francisco, California 94080
(650) 443-7400
(Address of Principal Executive Offices) (Zip Code)
2015 Equity Incentive Plan
2019 Equity Incentive Plan
2019 Employee Stock Purchase Plan
2022 Inducement Plan
(Full title of the plans)
Kelly E.W. Grez
Assistant Secretary
Harpoon Therapeutics, Inc.
611 Gateway Boulevard, Suite 400
South San Francisco, California 94080
(650) 443-7400
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Catherine Dargan
Andrew
Fischer
Michael Riella
Covington & Burling LLP
One CityCenter
850 Tenth
Street, NW
Washington, DC 20001
(202) 662-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐